Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam-Cefepime (WCK 5222) for Treatment of Serious Gram-Negative Infections .
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt has filed a New Drug Application (NDA) with the U.S. FDA seeking approval for Zidebactam-Cefepime, branded WCK 5222. The drug is intended to treat serious Gram-negative bacterial infections, which are a growing concern due to antibiotic resistance. This submission marks a key regulatory milestone in bringing the product to the lucrative U.S. pharmaceutical market. The company is positioning the therapy as a potential solution against multidrug-resistant infections where treatment options are limited.
This is a positive development for Wockhardt shareholders, as U.S. FDA acceptance and potential approval could unlock a large, high-value market. However, the stock impact may be muted until the FDA accepts the application and moves toward a clear approval timeline.